Drug Trial Radar · NCT06795204
Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT)
Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Apr 9, 2024
Primary completion
May 19, 2024
Study completion Nov 26, 2024
Sponsor
- Lead sponsor
- Haisco-USA Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To assess the effects of a single IV bolus of HSK3486 single dose on cardiac repolarization (QTc interval of the electrocardiogram, and to evaluate the safety and tolerability of a single IV bolus of HSK3486 in healthy subjects
Conditions
- Anesthesia; Adverse Effect
- Cardiac Arrhythmia
Interventions
HSK3486Drug
Study Drug
Moxifloxacin HydrochlorideDrug
Positive Control
PlaceboDrug
Negative Control
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change-from-baseline in QTc IntervalTime frame: From the base line ECG (D-2) to end of the period, up to 24 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Gobroad Boren Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.